论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
基于白蛋白结合型紫杉醇的化疗在晚期上皮样血管内皮瘤治疗中的应用:单中心经验
Authors Liu X , Yang P, Liu L, Si S, Zhou R, Liu T , Tan H
Received 12 December 2024
Accepted for publication 18 February 2025
Published 21 February 2025 Volume 2025:17 Pages 373—381
DOI https://doi.org/10.2147/CMAR.S508673
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Xiaolei Liu,* Peijun Yang,* Liguo Liu, Shuang Si, Ruiquan Zhou, Tiantong Liu, Haidong Tan
Second Department of Hepatopancreatobiliary Surgery, China-Japan Friendship Hospital, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaolei Liu; Haidong Tan, Second Department of Hepatopancreatobiliary Surgery, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Beijing, 100029, People’s Republic of China, Email liuxiaolei0302@126.com; hpblt_cjfh@126.com
Objective: To evaluate the clinical efficacy of nab-paclitaxel based chemotherapy in the treatment of advanced epithelioid hemangioendothelioma (EHE).
Methods: Since March 2022, chemotherapy has been recommended for patients with advanced EHE characterized by large tumors (liver tumors > 10 cm or tumors in other organs > 3 cm), rapid tumor progression, severe symptoms, serosal effusion, and treatment failure. Two chemotherapy regimens were administered: nab-paclitaxel plus bevacizumab and nab-paclitaxel plus sirolimus. Clinical data and outcomes were retrospectively analyzed.
Results: From March 2022 to August 2024, 21 patients with histologically confirmed EHE who received nab-paclitaxel based chemotherapy were included. At baseline, 18 patients (85.7%) presented with tumor-related symptoms, and serosal effusion was detected in 12 patients (57.1%). Among patients with hepatic EHE, six (28.6%) had tumors > 10 cm, while six (28.6%) with EHE at other sites had tumors > 3 cm. Partial response and stable disease were achieved in 5 (23.8%) and 12 (57.1%) patients, respectively, resulting in a disease control rate of 80.9%. Symptom relief was observed in 15 of 18 patients (83.3%), and decreased serosal effusion was noted in 6 of 12 patients (50.0%). The 1- and 2-year progression-free survival rates were 50.7% and 13.5%, respectively, while the 1- and 2-year overall survival rates were 70.6% and 51.5%, respectively.
Conclusion: Nab-paclitaxel based chemotherapy may offer an effective treatment option for patients with advanced EHE exhibiting adverse prognostic factors. However, further clinical trials are required to confirm its efficacy.
Keywords: epithelioid hemangioendothelioma, EHE, chemotherapy, sarcoma, survival